Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 11/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21084133 | 1.00 | HDAC11 (0.47) | HDAC11HDAC6HDAC1HDAC8ITGB3 | |
| SCHEMBL18144983 | 0.93 | HDAC11 (0.52) | HDAC11HDAC6HDAC1HDAC8LMNA | |
| SCHEMBL18144751 | 0.93 | HDAC11 (0.52) | HDAC11HDAC6HDAC1HDAC8LMNA | |
| SCHEMBL21084135 | 0.89 | HDAC6 (0.55) | HDAC11HDAC6HDAC1HDAC8ITGB3 | |
| SCHEMBL21084087 | 0.89 | HDAC6 (0.55) | HDAC11HDAC6HDAC1HDAC8ITGB3 | |
| SCHEMBL21084130 | 0.87 | HDAC6 (0.46) | HDAC11HDAC6HDAC1HDAC8ITGB3 | |
| SCHEMBL21084136 | 0.87 | HDAC6 (0.46) | HDAC11HDAC6HDAC1HDAC8ITGB3 | |
| SCHEMBL21084094 | 0.82 | HDAC6 (0.50) | HDAC11HDAC6HDAC1HDAC8 | |
| SCHEMBL21084126 | 0.82 | HDAC6 (0.50) | HDAC11HDAC6HDAC1HDAC8 | |
| SCHEMBL18145088 | 0.82 | HDAC6 (0.51) | HDAC11HDAC6HDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3472131-B1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | claimed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | claimed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | claimed |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO EARLY DISCOVERY, INC. | 2023-12-28 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO HEALTH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-06-24 | — | — | US | disclosed |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | VALO HEALTH, INC. | 2021-06-24 | — | — | US | disclosed |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | disclosed |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2020-04-23 | — | — | US | disclosed |
| EP-3472131-B1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | FORMA THERAPEUTICS INC (US) | 2020-02-19 | — | — | EP | disclosed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | Valo Health, LLC | 2019-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414585-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-20210186940-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-10874649-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-10555935-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-20190201384-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-12213969-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-20200121655-A1 | 2-SPIRO-5- AND 6-HYDROXAMIC ACID INDANES AS HDAC INHIBITORS | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
| US-11730721-B2 | 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors | HDAC5, HDAC2, HDAC1 | HDAC11 5/4885HDAC6 4/4885HDAC1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.